Ticiana Leal, MD

One star
One star
One star
One star
One half star

Rating: 4.8 out of 5 (184 ratings)

Role

Medical Oncology
Specialty

Lung Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2009

Call 404-778-1900

Background

Ticiana Leal, MD is associate professor and serves as director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in medical oncology and palliative care, Dr. Leal specializes in caring for patients with lung cancer, mesothelioma and thymic malignancies at Winship Cancer Institute.

Dr. Leal holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, Eastern Cooperative Oncology Group, European Society of Medical Oncology, Society for Immunotherapy of Cancer, and International Association for the Study of Lung Cancer. She is the NCI LUNG-MAP Chair, ECOG-ACRIN representative.

Before joining Emory, Dr. Leal was a member of the faculty at UW Carbone Cancer Center in Madison, Wisconsin, where she served as team leader of the Thoracic Malignancies Disease Oriented Team.

Dr. Leal received her medical degree from Federal University of Ceara in Fortaleza, Brazil. She completed her residency in internal medicine at Weiss Memorial Hospital in Chicago, Illinois. She completed a fellowship in geriatric medicine at the University of Illinois at Chicago, and a fellowship in medical oncology at the University of Wisconsin Hospitals and Clinics in Madison, Wisconsin.

Dr. Leal's clinical research focuses on clinical trials of chemotherapy and/or immunotherapy agents to treat cancers of the lung.

Dr. Leal has authored or coauthored numerous peer-reviewed original research articles, book chapters and posters. She serves as associate editor and as a member of the executive editorial board of The Journal of the National Comprehensive Cancer Network. She also serves as Lung Cancer Section Editor of Current Treatment Options in Oncology and on the editorial advisory boards of Cancer and The Brazilian Journal of Oncology.

PubMed

Titles & Roles

Associate Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Director, Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology

Emory University School of Medicine
Leader, Lung Cancer Disease Team

Winship Cancer Institute of Emory University

Education & Training

Education

Fellowship, Medical Oncology, 2009
University of Wisconsin
Fellowship, Geriatric Medicine, 2007
University of Illinois at Chicago
Residency, Internal Medicine, 2006
Weiss Memorial Hospital
Medical Education, MD, 2001
Federal University of Ceara

View Current Clinical Trials


Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Phase I Conditions NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer Location Winship Cancer Institute
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation Phase I Conditions Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation Location Winship Cancer Institute
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors Phase I Conditions Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency Location Winship Cancer Institute
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial Phase II Conditions Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm Location Winship Cancer Institute
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection Phase III Conditions Non-Small Cell Lung Cancer Location Winship Cancer Institute
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Phase I Conditions Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation Location Emory University Hospital Midtown, Winship Cancer Institute
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Phase III Conditions Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Location Emory University Hospital Midtown, Winship Cancer Institute
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer Phase I Conditions Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Location Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Phase II Conditions Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7 Location Emory University Hospital Midtown, Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	J Carlisle, Y Liu, T Leal	06/04/2024
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best. Cancer	TA Leal, SS Ramalingam	06/01/2024
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial. International journal of radiation oncology, biology, physics	MF Bassetti, BA Morris, N Sethakorn, JM Lang, JL Schehr, SG Zhao, ZS Morris, D Buehler, JC Eickhoff, PM Harari, AM Traynor, TC Campbell, AM Baschnagel, TA Leal	04/01/2024
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. The Journal of clinical investigation	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	03/07/2024
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan. JCO global oncology	TA Leal, A Dasgupta, D Latremouille-Viau, C Rossi, P Rai, F Barlesi, SV Liu	03/01/2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	AH Nassar, SY Kim, JV Aredo, J Feng, F Shepherd, C Xu, D Kaldas, JE Gray, TJ Dilling, JW Neal, HA Wakelee, Y Liu, SH Lin, T Abuali, A Amini, Y Nie, T Patil, A Lobachov, J Bar, B Fitzgerald, Y Fujiwara, TU Marron, R Thummalapalli, H Yu, DH Owen, J Sharp, S Farid, P Rocha, E Arriola, A D'Aiello, H Cheng, R Whitaker, K Parikh, Y Ashara, L Chen, K Sankar, JP Harris, M Nagasaka, A Ayanambakkam, AI Velazquez, M Ragavan, JJ Lin, Z Piotrowska, M Wilgucki, J Reuss, H Luders, C Grohe, J Baena Espinar, E Feiner, SR Punekar, S Gupta, T Leal, DJ Kwiatkowski, RH Mak, E Adib, AR Naqash, SB Goldberg	01/24/2024
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer. Cancer	NS McCall, JR Janopaul-Naylor, HS McGinnis, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, TA Leal, SS Ramalingam, JD Bradley, KA Higgins	12/01/2023
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply. The Lancet. Oncology	T Leal, C Langer	12/01/2023
Advancing immunotherapy in small cell lung cancer. Cancer	JW Carlisle, T Leal	11/15/2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO precision oncology	R Vaidya, JM Unger, L Qian, K Minichiello, RS Herbst, DR Gandara, JW Neal, TA Leal, JD Patel, KH Dragnev, SN Waqar, MJ Edelman, EV Sigal, SJ Adam, S Malik, CD Blanke, ML LeBlanc, K Kelly, JE Gray, MW Redman	09/01/2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. The Lancet. Oncology	T Leal, R Kotecha, R Ramlau, L Zhang, J Milanowski, M Cobo, J Roubec, L Petruzelka, L Havel, S Kalmadi, J Ward, Z Andric, T Berghmans, DE Gerber, G Kloecker, R Panikkar, J Aerts, A Delmonte, M Pless, R Greil, C Rolfo, W Akerley, M Eaton, M Iqbal, C Langer	09/01/2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	K He, D Berz, SM Gadgeel, WT Iams, DS Bruno, CM Blakely, AI Spira, MR Patel, DM Waterhouse, DA Richards, A Pham, R Jotte, DS Hong, EB Garon, A Traynor, P Olson, L Latven, X Yan, R Shazer, TA Leal	07/01/2023
Spotlight on Small-Cell Lung Cancer and Other Lung Neuroendocrine Neoplasms. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	L Fernandez-Cuesta, A Sexton-Oates, L Bayat, M Foll, SCM Lau, T Leal	05/01/2023
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer. Cancer	LC Villaruz, GR Blumenschein, GA Otterson, TA Leal	05/01/2023
A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Clinical lung cancer	WT Iams, ML Balbach, S Phillips, A Sacher, C Bestvina, V Velcheti, X Wang, ME Marmarelis, N Sethakorn, T Leal, PE Sackstein, C Kim, MA Robinson, K Mehta, R Hsu, J Nieva, T Patil, DR Camidge	05/01/2023
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. Cancer	T Salous, NA Shukla, SK Althouse, SM Perkins, M Furqan, T Leal, AM Traynor, LE Feldman, NH Hanna, GA Durm	01/15/2023
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. The New England journal of medicine	R Yaeger, J Weiss, MS Pelster, AI Spira, M Barve, SI Ou, TA Leal, TS Bekaii-Saab, CP Paweletz, GA Heavey, JG Christensen, K Velastegui, T Kheoh, H Der-Torossian, SJ Klempner	01/05/2023
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy. Expert review of anticancer therapy	T Leal, MA Socinski	01/01/2023
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). Cancer medicine	TA Leal, MN Sharifi, N Chan, R Wesolowski, AA Turk, JY Bruce, RM O'Regan, J Eickhoff, LM Barroilhet, J Malhotra, J Mehnert, E Girda, E Wiley, N Schmitz, S Andrews, G Liu, KB Wisinski	11/01/2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clinical lung cancer	BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam	11/01/2022
A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Clinical lung cancer	F Ardeshir-Larijani, SK Althouse, T Leal, LE Feldman, TA Hejleh, M Patel, RD Gentzler, AR Miller, NH Hanna	11/01/2022
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	NS McCall, HS McGinnis, JR Janopaul-Naylor, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, T Leal, SS Ramalingam, JD Bradley, KA Higgins	09/01/2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SI Ou, PA Jänne, TA Leal, II Rybkin, JK Sabari, MA Barve, L Bazhenova, ML Johnson, KL Velastegui, C Cilliers, JG Christensen, X Yan, RC Chao, KP Papadopoulos	08/10/2022
Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	TA Leal, SE Dahlberg, SS Ramalingam	07/20/2022
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell reports. Medicine	TA Leal, SS Ramalingam	07/19/2022
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature medicine	ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan, S Hu, YK Chae, TA Leal, JE Dowell, ML Tsai, CSR Dakhil, P Stella, Y Jin, DS Shames, E Schleifman, DA Fabrizio, S Phan, MA Socinski	05/01/2022
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer. Biomarker research	JL Schehr, N Sethakorn, ZD Schultz, CI Hernandez, RM Bade, D Eyzaguirre, A Singh, DJ Niles, L Henderson, JW Warrick, SM Berry, KE Sundling, DJ Beebe, TA Leal, JM Lang	04/25/2022
Corrigendum: Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound. Frontiers in rehabilitation sciences	J Lortie, B Rush, K Osterbauer, TJ Colgan, D Tamada, S Garlapati, TC Campbell, A Traynor, T Leal, V Patel, JJ Helgager, K Lee, SB Reeder, AJ Kuchnia	01/01/2022
Myosteatosis as a Shared Biomarker for Sarcopenia and Cachexia Using MRI and Ultrasound. Frontiers in rehabilitation sciences	J Lortie, B Rush, K Osterbauer, TJ Colgan, D Tamada, S Garlapati, TC Campbell, A Traynor, T Leal, V Patel, JJ Helgager, K Lee, SB Reeder, AJ Kuchnia	01/01/2022
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts. Molecular cancer therapeutics	AM Baschnagel, JH Elnaggar, HJ VanBeek, AC Kromke, JH Skiba, S Kaushik, L Abel, PA Clark, CA Longhurst, KP Nickel, TA Leal, SG Zhao, RJ Kimple	11/01/2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	J Malhotra, P Nikolinakos, T Leal, J Lehman, D Morgensztern, JD Patel, JM Wrangle, G Curigliano, L Greillier, ML Johnson, N Ready, G Robinet, S Lally, D Maag, R Valenzuela, V Blot, B Besse	09/01/2021
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, M Gottfried, N Peled, A Tafreshi, S Cuffe, M O'Brien, S Rao, K Hotta, TA Leal, JW Riess, E Jensen, B Zhao, MC Pietanza, JR Brahmer	07/20/2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	M Boyer, MAN Şendur, D Rodríguez-Abreu, K Park, DH Lee, I Çiçin, PF Yumuk, FJ Orlandi, TA Leal, O Molinier, N Soparattanapaisarn, A Langleben, R Califano, B Medgyasszay, TC Hsia, GA Otterson, L Xu, B Piperdi, A Samkari, M Reck	07/20/2021
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN	DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, DS Bruno, JY Chang, LR Chirieac, TA D'Amico, TJ Dilling, J Dowell, S Gettinger, MA Gubens, A Hegde, M Hennon, RP Lackner, M Lanuti, TA Leal, J Lin, BW Loo, CM Lovly, RG Martins, E Massarelli, D Morgensztern, T Ng, GA Otterson, SP Patel, GJ Riely, SE Schild, TA Shapiro, AP Singh, J Stevenson, A Tam, J Yanagawa, SC Yang, KM Gregory, M Hughes	03/02/2021
Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. Clinical lung cancer	TL Enright, JS Witt, AR Burr, P Yadav, T Leal, AM Baschnagel	03/01/2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, MC Garassino, J De Castro Carpeno, R Califano, M Nishio, F Orlandi, J Alatorre-Alexander, T Leal, Y Cheng, JS Lee, S Lam, M McCleland, Y Deng, S Phan, L Horn	02/20/2021
Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. Scientific reports	AM Baschnagel, S Kaushik, A Durmaz, S Goldstein, IM Ong, L Abel, PA Clark, Z Gurel, T Leal, D Buehler, G Iyer, JG Scott, RJ Kimple	01/28/2021

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.8	One star One star One star One star One half star	Provider showed concern
4.8	One star One star One star One star One half star	Provider explained things clearly
4.8	One star One star One star One star One half star	Provider discussed treatment options
4.8	One star One star One star One star One half star	Provider included you in decisions
4.8	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/30/2024	Good visit.
One star One star One star One star One star	05/19/2024	Dr Leal is the best
One star One star One star One star One half star	05/02/2024	I would have said very good but radiology did not have my of my ct scan that was done a week before. Dr said they were short of staff. Not acceptable.
One star One star One star One star One star	04/28/2024	She is a wonderful doctor, but whoever does her scheduling did a very poor job
One star One star One star One star One star	04/27/2024	Fell in love with Dr. Leal. She was frank when discussing our situation, direct in answering questions. Asked questions we hadn't thought to consider, etc. We are excited to have her as part of our team.
One star One star One star One star One star	04/26/2024	Very smart and helpful thank you
One star One star One star One half star Empty star	04/14/2024	Dr. Leal knows what she's doing and doesn't like to be told how to do her job she loves lungs and doesn't play with them she very passionate about it
One star One star One star One star One star	03/29/2024	We love Dr. Leal! She listens and cares about my symptoms and works with me and other doctors to alleviate my side effects. We highly recommend her!
One star One star One star One star One star	03/29/2024	Love everything about them
One star One star One star One star One star	02/17/2024	Dr Leal is outstanding!
One star One star One star One star One star	01/28/2024	Good
One star One star One star One star One star	01/20/2024	I thought Dr. Leal was very informative in discussing treatment options for me and made me very comfortable in the process.
One star One star One star One star One star	12/09/2023	Dr. Leal was exceptional during the entire appointment. She explained several possibilities and took the time to answer any questions that we asked. She explained several options we could take going forward.
One star One star One star One star One star	12/08/2023	Dr. Lean is terrific.
One star One star One star One star One star	12/03/2023	Dr Leal is the best, she explains stuff in a way that I can understand and is a special person
One star One star One star One star One star	11/11/2023	Dr. Leal is exceptional! I am lucky to have her as my doctor.
One star One star One star One star One star	10/21/2023	Dr Leal is thorough, caring, good humored!!
One star One star One star One star One star	10/20/2023	Dr Leal is the very best
One star One star One star One star One star	08/27/2023	Dr Leal is the best
One star One star One star One star One star	07/30/2023	Dr. Ticiana Leal is an excellent physician/pulmonary oncologist. I trust her implicitly and know that she is prescribing the best treatment designed for my situation.
One star One star One star One star One star	07/25/2023	Very thankful to Dr. Leal
One star One star One star One star One star	07/22/2023	Doctor Leal always answers any questions or concerns in a understanding manner. Shows compassion. Very informative.
One star One star One star One star One star	07/16/2023	Dr Leal explained everything in a way we could do understand and made us feel at ease
One star One star One star One star One star	06/10/2023	Great doctor very knowledgeable , caring, took time to ask questions Gave informative and direct explanations. Like this doctor.
One star One star One star One star One star	05/12/2023	Dr. Leal is my superhero.
One star One star One star One star One star	03/18/2023	Dr. Leal is outstanding!
One star One star One star One star One star	01/27/2023	Dr. Leal was personable, professional and knowledgeable. She listened well.
One star One star One star One star One half star	12/22/2022	Good
One star One star One star One star One star	09/20/2022	Dr. Leal was very pleasant, attentive, and fully answered my questions. I did not feel rushed at all.
One star One star One star One star One star	09/08/2022	I absolutely LOVE Dr Leal! She explained some challenging news (cancer spread) with my mom and I with a lot of care and compassion. Sitting with her in person made me feel like my mom was truly being cared for by someone with experience regarding her rare form of cancer. We LOVE HER!
One star One star One star One star One star	09/01/2022	I am so grateful for the service I received
One star One star One star Empty star Empty star	08/04/2022	My care provider was highly recommended to me. I believe she is well informed on her area of specialty and I trust she will give me the best treatment possible. I have had difficulty in getting information about my treatment plan and I have not felt particularly connected to her. She has lots on information but I rarely feel that she is interested in my feelings. And she is gone a good bit and I see her PA. The last visit I had was very short because of the length of time to check in but I did feel more of a connection with her on that visit. I am not unhappy with her, I'm adjusting to her style. I trust her knowledge.
One star One star One star One star One star	07/06/2022	Dr Leal is very caring and compassionate. Couldn't be more pleased with having her as my physician.
One star One star One star One star One star	06/30/2022	Very good